文献速递皮肤肿瘤

原发性皮肤黑色素瘤中早期溃疡的预后意义

Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma.
PubMed 文献 · JAMA Dermatol · 2023-01-01

该病例对照研究纳入2005-2015年切除的原发性皮肤黑色素瘤,比较早期溃疡(incipient ulceration)与无溃疡及溃疡对照的预后。匹配队列显示无溃疡者OS和RFS优于早期溃疡,溃疡者RFS劣于早期溃疡;调整病理因素后差异无统计学意义。

要点

  • 早期溃疡应被病理医生在报告中注明,并考虑纳入未来指南。
  • 早期溃疡的Breslow厚度和核分裂率介于无溃疡与溃疡之间。
  • 匹配分析中无溃疡者OS和RFS显著优于早期溃疡者。

核心结论

  • 原发性黑色素瘤中的早期溃疡是不良预后特征,应被病理医生报告并考虑纳入指南。

研究设计与样本

  • 病例对照研究,纳入2005-2015年切除的原发性皮肤黑色素瘤,来自Melanoma Institute Australia数据库且切片可复核。
  • 共识别2284例患者,340例符合标准;匹配队列含40例早期溃疡、80例无溃疡对照和80例溃疡对照(1:2匹配)。

主要发现

  • 中位Breslow厚度:早期溃疡2.8(1.7-4.1)mm,无溃疡1.0(0.6-2.1)mm,溃疡5.3(3.5-8.0)mm。
  • 中位肿瘤核分裂率:早期溃疡5.0(3.0-9.0)/mm²,无溃疡1(0-3.0)/mm²,溃疡9(5.0-14.0)/mm²。
  • 匹配队列中,无溃疡者OS显著优于早期溃疡(HR 0.49;95%CI 0.27-0.88;P=.02)。
  • 匹配队列中,无溃疡者RFS显著优于早期溃疡(HR 0.37;95%CI 0.22-0.64;P<.001)。
  • 溃疡者RFS显著劣于早期溃疡(HR 1.67;95%CI 1.07-2.60;P=.03)。

关键数值与推荐

  • 调整病理因素后,早期溃疡与任一对照组的临床结局均无统计学显著差异。
  • 早期溃疡不满足AJCC溃疡定义,通常被归类为无溃疡。

临床怎么用

  • 病理医生应在报告中注明早期溃疡,因其提示不良预后。
  • 未来指南制定时应考虑早期溃疡的预后意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ulceration represents a key feature in cutaneous melanoma, contributing to staging according to the current American Joint Committee on Cancer (AJCC) system. However, cases with incipient ulceration do not quite fulfill the AJCC definition of ulceration and are consequently classified as nonulcerated, presenting interpretive difficulty for pathologists. The prognostic implication of incipient ulceration is uncertain. OBJECTIVE: To evaluate the prognostic significance of incipient ulceration in cutaneous melanoma. DESIGN, SETTING, AND PARTICIPANTS: This case-control study consisted of resected primary cutaneous melanomas diagnosed between 2005 and 2015, identified from the Melanoma Institute Australia research database and with slides available for review at Royal Prince Alfred Hospital. Slides were reviewed by pathologists experienced in the diagnosis of melanocytic lesions to identify cases (incipient ulceration) and controls (ulcerated or nonulcerated). Incipient ulceration cases were matched at a 1:2 ratio with nonulcerated and ulcerated controls, respectively. Study analysis was conducted from March to June 2023. MAIN OUTCOMES: Clinicopathological factors and clinical outcomes: overall survival (OS), melanoma-specific survival (MSS), and recurrence-free survival (RFS) were compared between cases and controls. RESULTS: Of 2284 patients with melanoma identified, 340 patients (median [IQR] age, 69 [24-94] years; 136 [68%] men; median follow-up, 7.2 years) met the criteria. The matched cohort consisted of 40 cases of incipiently ulcerated melanoma matched 1:2 with 80 nonulcerated controls, and 80 ulcerated controls. The median (IQR) Breslow thickness differed significantly between cases and controls; 2.8 (1.7-4.1) mm for incipient cases compared with 1.0 (0.6-2.1) mm and 5.3 (3.5-8.0) mm for nonulcerated and ulcerated melanomas, respectively. Median (IQR) tumor mitotic rate was 5.0 (3.0-9.0) per mm2 in incipiently ulcerated cases compared with 1 (0-3.0) per mm2 in nonulcerated controls and 9 (5.0-14.0) per mm2 in ulcerated controls. Based on the matched cohorts, patients with nonulcerated tumors had significantly better OS (hazard ratio [HR], 0.49; 95% CI, 0.27-0.88; P = .02) and RFS (HR, 0.37; 95% CI, 0.22-0.64; P < .001) than patients with incipient ulceration. The RFS was significantly worse in ulcerated tumors compared with incipiently ulcerated cases (HR, 1.67; 95% CI, 1.07-2.60; P = .03). After adjusting for pathological factors, no statistically significant differences in clinical outcomes were observed between cases and either control group. CONCLUSIONS AND RELEVANCE: The findings of this case-control study indicate that incipient ulceration in a primary melanoma represents an adverse prognostic feature that should be noted by pathologists in their reports and considered in future guidelines.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Paver EC, Ahmed T, Burke H, et al. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma. JAMA Dermatol. 2023. PMID: 37910123. doi:10.1001/jamadermatol.2023.4193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。